90‐yttrium‐ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high‐risk follicular lymphoma: updated long‐term results after a median follow‐up of 7 years

Radioimmunotherapy (RIT) after an induction phase with conventional chemoimmunotherapy became an attractive strategy of consolidation for patients with advanced follicular lymphoma: in particular, in many studies RIT was represented by yttrium‐90‐ibritumomab tiuxetan ((90)Y‐IT). Independently by the...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Cancer Med
Main Authors: Casadei, Beatrice, Pellegrini, Cinzia, Pulsoni, Alessandro, Annechini, Giorgia, De Renzo, Amalia, Stefoni, Vittorio, Broccoli, Alessandro, Gandolfi, Letizia, Quirini, Federica, Tonialini, Lorenzo, Morigi, Alice, Argnani, Lisa, Zinzani, Pier Luigi
פורמט: Artigo
שפה:Inglês
יצא לאור: John Wiley and Sons Inc. 2016
נושאים:
Clinical Cancer Research
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4924367/
https://ncbi.nlm.nih.gov/pubmed/26990782
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.684
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים